Manipal Hospitals
| インド | トルコ | オーストリア | |
| 横紋筋肉腫摘出術 | から $4,500 | から $15,000 | から $30,000 |
| 放射線療法 | から $4,500 | から $3,250 | から $18,000 |
| 大腸癌に対する放射線療法 | から $3,200 | から $7,000 | から $12,000 |
| 乳癌化学療法 | から $3,500 | から $1,200 | から $15,000 |
| 横紋筋肉腫の複合治療 | から $25,000 | から $45,000 | - |
Bookimedは横紋筋肉腫治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。横紋筋肉腫治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。横紋筋肉腫治療の旅路でお一人になることはありません。
Treating rhabdomyosarcoma in India involves a multidisciplinary team led by pediatric or medical oncologists. These experts coordinate chemotherapy protocols at NABH-accredited facilities. Specialized surgeons, radiation oncologists, and pathologists collaborate within tumor boards. This ensures precise staging and local control for various tumor locations.
Bookimed Expert Insight: Manipal Hospitals and Global Hospital Chennai manage over 80,000 patients annually. Our data shows these large tertiary centers offer integrated teams under one roof. This is vital because rhabdomyosarcoma requires immediate coordination between pathology and surgery. Choosing a multi-specialty group prevents delays in starting risk-adapted treatment protocols.
Patient Consensus: Patients note that a tumor board approach is the standard for managing this complex cancer. They emphasize that while one doctor often starts the process, a full team handles the treatment.
Indian hospitals offer multimodal rhabdomyosarcoma treatment including risk-adapted chemotherapy, surgery, and advanced radiation. Facilities like Manipal Hospitals and Fortis Gurgaon use international protocols from the Childrens Oncology Group. This approach ensures high standards for pediatric oncology care and localized tumor control.
Bookimed Expert Insight: Patient volume is a major indicator of expertise in India. Global Hospital Chennai and Manipal Hospitals each serve 2,000,000 patients annually. This massive scale allows oncologists to manage rare cases like rhabdomyosarcoma more frequently than smaller centers. When choosing a facility, look for those with dedicated pediatric departments like Fortis Gurgaon, which is recognized globally for its technical advancement.
Patient Consensus: Patients note it is vital to seek care at specialized sarcoma centers rather than general hospitals. They emphasize that treatment plans are highly individualized based on the tumor's specific location and response to initial chemotherapy.
Top Indian hospitals for rhabdomyosarcoma treatment are located in Bengaluru, Gurgaon, Chennai, and Mumbai. These major medical hubs host facilities with NABH and JCI accreditations. Specialized centers feature dedicated pediatric oncology units equipped for complex chemotherapy and advanced radiation protocols.
Bookimed Expert Insight: While Mumbai and Delhi are traditional hubs, Bengaluru and Chennai have emerged as high-capacity alternatives. Clinics like Manipal Hospitals and Global Hospital Chennai manage over 2,000,000 patients every year. These facilities often provide greater bed availability for long-term childhood cancer treatments compared to overcrowded government centers.
Patient Consensus: Patients emphasize choosing dedicated pediatric programs over general hospitals for rare sarcomas. Many note it is vital to secure second pathology opinions before starting intensive chemotherapy or radiation.
India offers advanced rhabdomyosarcoma therapies including proton beam therapy and molecularly targeted treatments. Major oncology centers provide intensity-modulated radiation therapy to protect vital organs. Leading institutes also integrate immunotherapy and genetic profiling to tailor specific protocols for complex or relapsed pediatric cases.
Bookimed Expert Insight: Clinical volume serves as a critical quality indicator in India. Facilities like Manipal Hospitals and Global Hospital Chennai serve 2 million patients annually. This massive scale allows these institutions to maintain dedicated sarkoma units. These units often provide access to clinical trials for high-risk subtypes like alveolar rhabdomyosarcoma.
Patient Consensus: Patients emphasize starting standard treatment quickly rather than delaying care to search for experimental options. Many recommend getting a second opinion to confirm the pathology subtype before beginning advanced radiation.
Leading Indian hospitals for rhabdomyosarcoma treatment include Global Hospital Chennai. Fortis Gurgaon and HCG Manavata Cancer Centre are also included. These NABH-accredited facilities provide multidisciplinary care using TomoTherapy, PET-CT, and TrueBeam technology. Specialist oncology teams follow international protocols to manage surgery and intensive chemotherapy cycles.
Bookimed Expert Insight: Indian oncology hubs are shifting toward super-specialisation in paediatric sarcomas. Major centres like Manipal Hospitals serve 2,000,000 patients annually. However, HCG Manavata stands out by auditing its research institute through the US-FDA. This suggests these centres maintain global data standards for rare soft-tissue tumours like rhabdomyosarcoma.
Patient Consensus: Patients highlight that Indian specialists are first-rate for soft-tissue sarcomas. Many suggest having Australian pathology reviewed first. This can confirm embryonal or alveolar subtypes before starting chemotherapy.
Rhabdomyosarcoma success rates in India vary by risk group, with five-year survival between 40% and 77% overall. Low-risk tumours show 90% survival in leading Indian oncology centres. Intermediate-risk cases often see 70% survival through intensive chemotherapy, surgery, and specialised radiation therapy.
Bookimed Expert Insight: While India lacks sarcoma-specific CAR-T therapy, oncology units here specialise in massive surgical volumes. HCG Manavata Cancer Centre treats over 75,000 patients every year. This high volume allows specialists to refine complex surgical removals that smaller clinics cannot perform.
Patient Consensus: Patients in India note that tumour shrinkage during radiation takes time to show on scans. Management of intense nausea and fatigue is essential during the initial week of chemotherapy.
India provides advanced radiotherapy like proton therapy for rhabdomyosarcoma. The Apollo Proton Cancer Centre in Chennai specialises in this treatment. It uses pencil beam scanning to target tumours precisely. This technology protects healthy tissue in paediatric cases and reduces side effects.
Bookimed Expert Insight: Indian radiotherapy centres have a unique infrastructure advantage for paediatric cases. HCG Manavata Cancer Centre in Nashik treated over 75,000 patients. It also holds US-FDA audit approval for clinical research. This level of volume allows specialists to refine protocols for rare sarcomas. Smaller regional centres rarely see these sarcomas.
Patient Consensus: Families note that proton therapy effectively manages side effects during child oncology treatments in India. They also mention that standard radiotherapy combined with chemotherapy remains a reliable and manageable path. This is for alveolar rhabdomyosarcoma cases.
Rhabdomyosarcoma treatment in India uses a multimodal approach combining chemotherapy, surgical resection, and radiation therapy. Specialists like Dr Gaurav Kharya at Artemis Hospitals focus on paediatric cases. Indian centres provide rapid access to advanced PET-CT diagnostics. They also offer TrueBeam STx radiation to manage systemic spread.
Bookimed Expert Insight: Indian oncology centres often provide faster access to treatment than many Western systems. HCG Manavata Cancer Centre has performed over 65,000 surgeries and treated 25,000 radiation cases. This massive volume means Indian specialists manage rare rhabdomyosarcoma presentations more frequently. They manage them more often than specialists in smaller regional hubs.
Patient Consensus: Patients find that treatment in India often starts within days of diagnosis. They highlight that the year-long chemotherapy protocol alongside radiation is manageable with proper supportive care.
India provides specialised paediatric oncologists and multidisciplinary sarcoma teams at major cancer centres. These specialists manage childhood rhabdomyosarcoma using integrated chemotherapy, surgery, and radiation. They work within JCI or NABH-accredited hospitals. Facilities like HCG Manavata and Manipal Hospitals maintain dedicated paediatric oncology departments for these complex cases.
Bookimed Expert Insight: Many patients seek doctors in major hubs like Delhi or Mumbai. However, regional centres offer comparable technology. HCG Manavata in Nashik treats 75,000+ patients annually. It was the first in its region with TomoTherapy-H. This technology allows precise radiation that spares a child's developing healthy tissue during sarcoma treatment.
Patient Consensus: Families find it essential to choose hospitals with dedicated paediatric oncology departments. They prefer these over general ones. Patients recommend sharing full pathology reports with Indian specialists early. This helps confirm experience with specific rhabdomyosarcoma subtypes.
Clinical trials for Rhabdomyosarcoma are available in India. Leading centres such as HCG Manavata Cancer Centre and Tata Memorial Hospital actively run research. These trials often focus on paediatric oncology and soft tissue sarcomas. Many studies involve international collaborations, giving access to novel treatment protocols.
Bookimed Expert Insight: India excels in fast treatment initiation, with virtually no waiting times for chemotherapy. Some immunotherapy trials are limited to the US. Still, Indian centres like HCG Manavata serve 75,000+ patients each year. This high volume supports robust data collection in Phase 3 trials comparing new protocols against standard care.
Patient Consensus: Patients find that starting standard chemotherapy in India is incredibly fast. Most families focus on immediate surgery and chemo. They also check for novel agents like pan-KRAS inhibitors through local oncologists.